SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Possible Violations of Federal Securities Laws by Certain Officers and Directors of Lipocine, Inc.

NEW YORK--()--Levi & Korsinsky announces it has commenced an investigation of Lipocine, Inc. (NASDAQ: LPCN) concerning possible violations of federal securities laws.

On June 29, 2016, Lipocine announced that the U.S. Food and Drug Administration had issued a Complete Response Letter regarding the Company’s New Drug Application for the drug treatment LPCN 1021. According to the Complete Response Letter, the FDA has identified deficiencies related to the dosing algorithm for the label and concluded the application was not ready for approval in its present form. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/lipocine-lpcn

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com

Release Summary

Levi & Korsinsky announces it has commenced an investigation of Lipocine, Inc. concerning possible violations of federal securities laws.

Contacts

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com